Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 576-586

  Barr, Margaret C ^a,b   Huitron Resendiz, Salvador ^a   Selway, Donald R ^a,b   Henriksen, Steven J ^a   Phillips, Tom R ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Immune Complex Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; EVOKED BRAIN STEM RESPONSE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CATS; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; LYMPHOCYTE SUBSETS; METHYLPREDNISOLONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TUMOR NECROSIS FACTOR-ALPHA; VIREMIA;

EID: 0034007724     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315236     Document Type: Article

References (71)

1. Pedersen NC, Yamamoto JK, Ishida T, Hansen H. Feline immunodeficiency virus infection. Vet Immunol Immunopathol 1989; 21:111-29.
2. Billaud JN, Phillips TR. FIV. A lentivirus model for opiate effects on disease. Adv Exp Med Biol 1998; 437:101-16.
3. Elder JH, Dean GA, Hoover EA, et al. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998; 14:797-801.
4. Vitkovic L, Stover E, Koslow SH. Animal models recapitulate aspects of HIV/CNS disease. AIDS Res Hum Retroviruses 1995; 11:753-9.
5. Willett BJ, Flynn JN, Hosie MJ. FIV infection of the domestic cat: an animal model for AIDS. Immunol Today 1997; 18:182-9.
6. Lawrence CE, Callanan JJ, Willett BJ, Jarrett O. Cytokine production by cats infected with feline immunodeficiency virus: a longitudinal study. Immunology 1995; 85:568-74.
7. Barlough JE, Ackley CD, George JW, et al. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr 1991; 4:219-27.
8. Ackley CD, Yamamoto JK, Levy N, Pedersen NC, Cooper MD. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 1990; 64:5652-5.
9. Henriksen SJ, Prospero-Garcia O, Phillips TR, Fox HS, Bloom FE, Elder JH. Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Curr Top Microbiol Immunol 1995; 202:167-86.
10. Phillips TR, Prospero-Garcia O, Puaoi DL, et al. Neurological abnormalities associated with feline immunodeficiency virus infection. J Gen Virol 1994; 75:979-87.
11. Prospero-Garcia O, Herold N, Phillips TR, Elder JH, Bloom FE, Henriksen SJ. Sleep patterns are disturbed in cats infected with feline immunodeficiency virus. Proc Natl Acad Sci USA 1994; 91:12947-51.
12. Mitra D, Sikder SK, Laurence J. Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression. Virology 1995; 214:512-21.
13. Soudeyns H, Geleziunas R, Shyamala G, Hiscott J, Wainberg MA. Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology 1993; 194:758-68.
14. Brooke S, Chan R, Howard S, Sapolsky R. Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex. Proc Natl Acad Sci USA 1997; 94:9457-62.
15. Limoges J, Persidsky Y, Bock P, Gendelman HE. Dexamethasone therapy worsens the neuropathology of human immunodeficiency virus type 1 encephalitis in SCID mice. J Infect Dis 1997; 175:1368-81.
16. Rojko JL, Hoover EA, Mathes LE, Krakowka S, Olsen RG. Influence of adrenal corticosteroids on the susceptibility of cats to feline leukemia virus infection. Cancer Res 1979; 39:3789-91.
17. Podell M, Oglesbee M, Mathes L, Krakowka S, Olmstead R, Lafrado L. ATDS-associated encephalopathy with experimental feline immunodeficiency virus infection. J Acquir Immune Defic Syndr 1993; 6:758-71.
18. Bradley WG, Verma A. Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy. Neurology 1996; 47:1446-51.
19. Gopal DV, Hassaram S, Marcon NE, Kandel G. Idiopathic colonic inflammation in AIDS: an open trial of prednisone. Am J Gastroenterol 1997;92: 2237-40.
20. Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, Saag MS. Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. AIDS Res Hum Retroviruses 1997; 13:1533-7.
21. Neumann Y, Toren A, Mandel M, et al. Favorable response of pediatric AIDS-related Burkitt's lymphoma treated by aggressive chemotherapy. Med Pediatr Oncol 1993; 21:661-4.
22. Sleasman JW, Hemenway C, Klein AS, Barrett DJ, Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. Am J Dis Child 1993; 147:30-4.
23. Vega KJ, Bollu J, Dajani EZ, Trotman BW. Idiopathic esophageal ulceration in patients infected with human immunodeficiency virus. J Assoc Acad Minor Phys 1996; 7:93-8.
24. Watterson MK, Detwiler RK, Bolin P Jr. Clinical response to prolonged corticosteroids in a patient with human immunodeficiency virus associated nephropathy. Am J Kidney Dis 1997; 29:624-6.
25. Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 1994; 97:145-51.
26. Cohn LA. Glucocorticosteroids as immunosuppressive agents. Semin Vet Med Surg (Small Anim) 1997; 12:150-6.
27. Behrend EN, Kemppainen RJ. Glucocorticoid therapy. Pharmacology, indications, and complications. Vet Clin North Am Small Anim Pract 1997; 27:187-213.
28. Biglino A, Limone P, Forno B, et al. Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HTV-1 infection. Eur J Endocrinol 1995; 133:173-9.
29. Phillips TR, Talbott RL, Lamont C, Muir S, Lovelace K, Elder JH. Comparison of two host cell range variants of feline immunodeficiency virus. J Virol 1990; 64:4605-13.
30. Barr MC. FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Semin Vet Med Surg (Small Anim) 1996; 11:144-53.
31. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234:1563-6.
32. + T-cell-mediated suppression of HIV replication in the first year of life: association with lower viral load and favorable early survival. AIDS 1997; 11:F9-13.
33. + antiviral activity in cats infected with feline immunodeficiency virus. J Virol 1996; 70:2474-80.
34. Heine CW, Kelly DC, Avery RJ. The detection of intracellular retrovirus-like entities in Drosophila melanogaster cell cultures. J Gen Virol 1980; 49:385-95.
35. Diehl LJ, Mathiason-DuBard CK, O'Neil LL, Hoover EA. Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR. J Virol 1995; 69:2328-32.
36. Piatak M Jr, Luk KC, Williams B, Lifson JD. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 1993; 14:70-81.
37. Serth J, Panitz F, Herrmann H, Alves J. Single-tube nested competitive PCR with homologous competitor for quantitation of DNA target sequences: theoretical description of heteroduplex formation, evaluation of sensitivity, precision and linearrange of the method. Nucleic Acids Res 1998; 26:4401-8.
38. Kotake S, Schumacher HR Jr, Wilder RL. A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples. J Immunol Methods 1996; 199:193-203.
39. Hayward AL, Oefner PJ, Sabatini S, Kainer DB, Hinojos CA, Doris PA. Modeling and analysis of competitive RT-PCR. Nucleic Acids Res 1998; 26:2511-8.
40. Lehmann R, Joller H, Haagmans BL, Lutz H. Tumor necrosis factor alpha levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection. Vet Immunol Immunopathol 1992; 35:61-9.
41. Rimstad E, Reubel GH, Dean GA, Higgins J, Pedersen NC. Cloning, expression and characterization of biologically active feline tumour necrosis factor-alpha. Vet Immunol Immunopathol 1995; 45:297-310.
42. Bressler P, Poli G, Justement JS, Biswas P, Fauci AS. Glucocorticoids synergize with tumor necrosis factor alpha in the induction of HIV expression from a chronically infected promonocytic cell line. AIDS Res Hum Retroviruses 1993; 9:547-51.
43. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992; 8:191-7.
44. An SF, Scaravilli F. Early HIV-1 infection of the central nervous system. Arch Anat Cytol Pathol 1997; 45:94-105.
45. Chollet-Martin S, Simon F, Matheron S, Joseph CA, Elbim C, Gougerot-Pocidalo MA. Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 1994; 8:879-84.
46. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997; 18:418-24.
47. Ampel NM. Emerging disease issues and fungal pathogens associated with HIV infection. Emerg Infect Dis 1996; 2:109-16.
48. Nelson MR, Erskine D, Hawkins DA, Gazzard BG. Treatment with corticosteroids - a risk factor for the development of clinical cytomegalovirus disease in AIDS. AIDS 1993; 7:375-8.
49. + T cells. Immunol Today 1996; 17:217-24.
50. Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS. CD8 cell non-cytotoxic antiviral activity in human immunodeficiency virus-infected and uninfected children. J Infect Dis 1998; 177:470-2.
51. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271:324-8.
52. +antiviral response that correlates with reduction of cell-associated virus. J Infect Dis 1998; 177:18-25.
53. + T lymphocytes and enhance HIV-1 replication. J Leukoc Biol 1998; 64:642-9.
54. Poeschla EM, Looney DJ. CXCR4 is required by a nonprimate lentivirus: heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells. J Virol 1998; 72:6858-66.
55. Willet BJ, Picard L, Hosie MJ, Turner JD, Adema K, Clapham PR. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 1997; 71:6407-15.
56. Tachibana H, Kawabata K, Takeda M, Sugita M. Multimodal evoked potentials in Binswanger's disease and Alzheimer's disease. Int J Neurosci 1993; 69:197-206.
57. Tachibana H, Takeda M, Sugita M. Short-latency somatosensory and brainstem auditory evoked potentials in patients with Parkinson's disease. Int J Neurosci 1989; 44:321-6.
58. Tachibana H, Takeda M, Sugita M. Brainstem auditory evoked potentials in patients with multi-infarct dementia and dementia of the Alzheimer type. Int J Neurosci 1989; 48:325-31.
59. Boccellari AA, Dilley JW, Yingling CD, et al. Relationship of CD4 counts to neurophysiological function in HIV-1 infected homosexual men. Arch Neurol 1993; 50:517-21.
60. Phillips TR, Prospero-Garcia O, Wheeler DW, et al. Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR. J Neurovirol 1996; 2:388-96.
61. Hoheisel D, Nitz T, Franke H, el al. Hydrocortisone reinforces the blood- brain properties in a serum free cell culture system, Biochem Biophys Res Commun 1998; 247:312-5 [corrected article; supercedes Biochem Biophys Res Commun 1998;244:312-6].
62. Grabb PA, Gilbert MR. Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. J Neurosurg 1995; 82: 1053-8.
63. Wilekens T. Glucocorticoids and immune function: physiological relevance and pathogenic potential of hormonal dysfunction. Trends Pharmacol Sci 1995; 16:193-7.
64. Kong LY, Wilson BC, McMillian MK, Bing G, Hudson PM, Hong JS. The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. Cell Immunol 1996; 172:77-83.
65. Ilyin SE, Plata-Salaman CR. HIV-1 envelope glycoprotein 120 regulates brain IL-1 beta system and TNF-alpha mRNAs in vivo. Brain Res Bull 1997; 44:67-73.
66. Van der Meide PH, Schellekens H. Cytokines and the immune response. Biotherapy 1996; 8:243-9.
67. Fiala M, Looney DJ, Stins M, et al. TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med 1997; 3:553-64.
68. Kraus LA, Bradley WG, Engelman RW, Brown KM, Good RA, Day NK. Relationship between tumor necrosis factor alpha and feline immunodeficiency virus expressions. J Virol 1996; 70:566-9.
69. Hestdal K, Aukrust P, Muller F, et al. Dysregulation of membrane-bound tumor necrosis factor-alpha and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load. Blood 1997; 90:2670-9.
70. Nokta M, Rossero R, Loesch K, Pollard RB. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea. AIDS Res Hum Retroviruses 1997; 13:1633-8.
71. Schwiebert R, Fultz PN. Immune activation and viral burden in acute disease induced by simian immunodeficiency virus SIVsmmPBj 14: correlation between in vitro and in vivo events. J Virol 1994; 68:5538-47.